Week One of All Things Medical Auction Event Starts Monday, March 11, 2013 Conducted by IpAuctions™, Inc.

IpAuctions™, Inc. 1st Annual All Things Medical auction event focuses on the Medical Industry. The first week will feature University of Arkansas for Medical Sciences BioVentures.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Reno, NV (PRWEB) March 11, 2013

IpAuctions™, Inc. is proud to conduct the first annual All Things Medical and will be featuring the University of Arkansas to kick off the event. The Board of Trustees of the University of Arkansas is offering the following patents and applications.

Lot#1208 Human Cytoplasmic Polyadenylation Element Binding Protein Patent Portfolio.

Includes 3 US patents. Diagnostic and/or Therapeutic Tool - This discovery relates to the fields of molecular biology and gene cloning. Specifically relating to the identification, cloning, and characterization of the gene encoding human cytoplasmic polyadenylation element binding protein (hCPEB), with sequence-specific RNA binding activity.

Lot#1209 Patent for Diagnosis of Atypical Mycobacterial Infections.

Includes a single US patent. This novel method amplifies the rDNA of eleven different MOTT species in a single test and does not amplify M. tuberculosis DNA. This test can be applied directly on patient samples, both fresh and formalin-fixed, which greatly decreases the turnaround time.

Lot# 1210 Medical Patent For Method of Diagnosing Heart Disease.

Includes a single US patent. This invention integrates and refines a battery of sensitive and specific tests based on multi-fractal analysis and applies them to digitized EKG data to generate diagnostic/prognostic information. Useful results from these tests can be made available in 15 minutes or less (multi-fractal alpha – MFalpha) to several hours (MF Holder, or the related MF Cascade Coefficient, MFCC).

Lot#1211 Ovarian Cancer Diagnosis Portfolio.

Includes patents and patent applications in the US, Canada, Australia, European and WIPO. Now the University of Arkansas Biochemistry and Molecular Biology department has developed this ‘marker’, ready for further development and trials. The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. The detected proteases are themselves specifically over-expressed in certain cancers, and the presence of their genetic precursors may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.

Auctions open at Noon PST.


Contact

Attachments